Psychemedics Co. (NASDAQ:PMD) Major Shareholder Powell Anderson Capital Partne Buys 7,473 Shares

Psychemedics Co. (NASDAQ:PMD) major shareholder Powell Anderson Capital Partne acquired 7,473 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average cost of $2.59 per share, with a total value of $19,355.07. Following the completion of the purchase, the insider now owns 415,038 shares of the company’s stock, valued at $1,074,948.42. This trade represents a 1.83 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Powell Anderson Capital Partne also recently made the following trade(s):

• On Thursday, December 12th, Powell Anderson Capital Partne bought 75,000 shares of Psychemedics stock. The stock was acquired at an average cost of $2.67 per share, with a total value of $200,250.00.

Psychemedics Stock Down 1.8 %

PMD stock opened at $2.67 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.59 and a quick ratio of 1.59. The stock has a market capitalization of $15.73 million, a P/E ratio of -5.24 and a beta of 0.65. The business has a 50-day moving average of $2.38 and a 200-day moving average of $2.31. Psychemedics Co. has a fifty-two week low of $1.63 and a fifty-two week high of $3.93.

Psychemedics Company Profile

Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol.